Teva Pharmaceutical Industries Limited Credit Ratings :: Fitch Ratings
DEF 14A
Moody's Downgrades Teva Bond Rating to “Junk” | Ctech
Teva Announces $2,250,000,000 Debt Tender Offers for Notes Due 2023-2026 | Business Wire
Teva chief reports 'strong progress' in restructuring plan | The Times of Israel
Credit Trends: Downgrade Potential Rises To All-Time High On Sharp, Deep Economic Slowdown | S&P Global Ratings
Teva Hits FDA Hurdle, Slips 4.5% Pre-Market - TipRanks.com
Teva Pharm to stay as unified drugmaker, sees big interest in API business, says CEO
Teva Shakes Up C-Suite in Restructuring | BioSpace
Teva Reports Fourth Quarter and Full Year 2021 Financial Results | Business Wire
Rating Agencies Exacerbate The Covid Crisis for Sovereigns - Track Live Bond Prices Online with BondEValue App - credit downgrades, credit ratings, sovereign bonds, sovereign ratings
Sell Teva Pharmaceutical due to increasing generic drugs competition: Credit Suisse
S&P cuts Teva's rating on rising litigation risks - Globes
Credit Trends: Downgrade Potential Rises To All-Time High On Sharp, Deep Economic Slowdown | S&P Global Ratings
Credit Trends: Downgrade Potential Rises To All-Time High On Sharp, Deep Economic Slowdown | S&P Global Ratings
Teva Pharmaceutical Industries Ltd (ADR) Needs More Than Job Cuts
S&P Global Ratings affirms Teva Pharmaceutical Industries at "BB-" (Local Currency LT credit rating); outlook stable
Why Teva's Stock Could Crash Another 50% | BioSpace
Teva's Credit Rating Cut to Junk by Fitch - Bloomberg
TEVA Stock Sees Positive Momentum as Bank of America Analyst Maintains Strong Buy Rating | WallStreetZen
Teva shares approach 20-year low amid Moody's warning and other woes | Fierce Pharma
Fitch Downgrades Teva to Junk Rating | Ctech
Teva Pharmaceuticals has acquired success with Actavis Generics | World Finance
Teva Pharmaceutical S&P rating outlook changed to stable | Seeking Alpha
